An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial.

ABSTRACT:

Importance

Despite recent advances in treatment of severe aortic valve stenosis (AS), AS remains a life-threatening condition with no proven disease-modifying therapy. Low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) have been implicated in the pathobiology of AS. The proprotein convertase subtilisin/kexin type 9 inhibitor evolocumab reduces circulating LDL-C concentrations by 50% to 60% and Lp(a) by 20% to 30%.

Objective

To determine whether evolocumab reduces the risk of AS events in patients with atherosclerotic cardiovascular disease.

Interventions

Patients were randomized 1:1 to evolocumab or placebo.

Design, setting, and participants

Exploratory analysis of the FOURIER trial, which enrolled 27 564 patients with stable atherosclerotic

SUBMITTER: Bergmark BA 

PROVIDER: S-EPMC7301224 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature